SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 is driving the sharp selloff, raising concerns about pricing and CorMedixs largest revenue stream. Traders disagree over how much weight to give DaVitas preliminary outlook versus CMSs stated Q1 rate, with some calling the drop an overreaction and others questioning managements response and capital allocation.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS and triggered a sharp selloff. Traders debate whether the rival can erode PAPZIMEOS uptake or whether Precigens full approval, commercial head start, and established sales offer an advantage.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys latest quarterly results, supported by resilient theme-park performance and improving streaming profitability, have encouraged bullish reactions and analyst upgrades. Traders remain divided, with some seeing a recovery setup while others question whether the shares can sustain a move higher after years of range-bound performance.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias Q3 results and higher full-year revenue guidance are driving discussion, with traders pointing to continued LUPKYNIS growth and solid execution. Reactions are mixed: many view the report positively, while others are frustrated by the share-price decline and uncertainty over an earnings call; patent litigation and pipeline speculation are secondary topics.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal fourth-quarter results beat expectations, with resilient payment and cross-border activity, but traders are debating whether slower-growth guidance and a rich valuation temper the strong operating performance; reactions include sell-the-news caution alongside longer-term optimism.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a listed treasury vehicle tied to Hyperliquids HYPE token, with traders reacting to HYPEs rally to record levels while debating why PURR has lagged. Bulls point to its HYPE exposure and possible short-covering; bears cite potential dilution from share issuance and volatile price action.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms sharp decline is being discussed mainly as part of a broad semiconductor selloff linked by traders to Intels weak outlook, with some also pointing to Qualcomm-specific licensing costs and upcoming earnings uncertainty. Reactions are split between dip buyers who view the drop as sector-driven and holders concerned about the stocks continued weakness.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook, amid softer PC demand and manufacturing constraints, triggered a sharp selloff and analyst downgrades. Traders are divided between calling the drop an overreaction and buying the dip, and expecting further losses while questioning managements execution and the turnaround.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellass REGAL Phase 3 AML trial reached its prespecified 80th death event, triggering final analysis ahead of topline results. Traders are debating whether GPS improved survival versus best available treatment: bullish holders see reasons for optimism, while skeptics cite dosing changes and possible effects from transplants or censoring; the share-price decline after the milestone has sharpened that disagreement.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ais quarterly results are driving discussion: despite an adjusted EPS beat and positive free cash flow, revenue remained sharply lower year over year and the next-quarter outlook disappointed traders. The community is split between viewing stronger bookings and restructuring as signs of a turnaround and focusing on weak growth and continued losses; short-squeeze chatter is also prominent.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?

Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

Key PointsThe sale had an approximate value of nearly $350,000...

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates

Shionogi & Co. (SGIOY) delivered earnings and revenue surprises of +100.00% and -0.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers PR Newswire NEW YORK...

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Barclays raised its price target on Relay Therapeutics to $27 from $21 while maintaining an ‘Overweight’ rating, implying a potential upside of 124% from RLAY’s closing price on Tuesday.</li><li>The firm cited growing confidence in zovegalisib following the company’s latest clinical update.</li><li>Citizens said the data support a larger vascular anomalies opportunity and a potential accelerated approval pathway, with regulatory feedback expected in the second half of 2026.</li></ul>Relay Therapeutics Inc. (RLAY) shares declined more than 5% in Wednesday’s pre-market trade, extending the marginal decline on Tuesday, with the stock on track for its fifth consecutive trading session in the red.Relay Therapeutics announced that it had commenced an offering of $175 million worth of shares of its common stock late Tuesday. All of the shares in the stock offering are to be sold by the company, not by existing investors, it stated.<h2 class="st-heading-2">Wall Street Turns Bullish On RLAY</h2>According to TheFly, Barclays raised its price target on Relay Therapeutics to $27 from $21 while maintaining an ‘Overweight’ rating, implying a potential upside of 124% from RLAY’s closing price on Tuesday. The firm cited growing confidence in zovegalisib following the company’s latest clinical update.Barclays added that the mutant-selective cancer drug appears positioned as a potential “best-in-class” treatment for vascular anomaly patients, with an estimated $6 billion market opportunity, limited competition, and a possible accelerated regulatory pathway.Citizens raised its price target on Relay Therapeutics to $21 from $19 and reiterated an ‘Outperform’ rating after zovegalisib posted a 60% response rate at 12 weeks with improved tolerability versus alpelisib.The firm said the data support a larger vascular anomalies opportunity and a potential accelerated approval pathway, with regulatory feedback expected in the second half of 2026.Analysts at JonesResearch upgraded Relay Therapeutics to ‘Buy’ from ‘Hold’ and raised its price target to $20 from $18, citing the company’s clinical update.The firm said the results support zovegalisib’s efficacy potential and increased its estimated odds of success in vascular malformations to 40% from 20%.<h2 class="st-heading-2">RLAY’s Clinical Update For Zovegalisib</h2>Relay Therapeutics&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-rlay-stock-rising-today/cZXuoXhReZq">reported</a> initial Phase 2 data on Tuesday, showing that zovegalisib achieved a 60% volumetric response rate at 12 weeks in vascular anomalies patients, with nearly all patients experiencing symptomatic improvement.The mutant-selective PI3Kα drug also demonstrated a favorable safety and tolerability profile that may support chronic use.<h2 class="st-heading-2">How Did Retail Traders React To RLAY?</h2>Retail sentiment on Stocktwits around Relay Therapeutics trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user brushed off the decline in RLAY stock following the offering, stating that there is nothing to be concerned about.<stembedurl>https://stocktwits.com/GA09/message/653853122</stembedurl><a href="https://stocktwits.com/symbol/RLAY">RLAY stock</a> is up 43% year-to-date and 312% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 31% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 59%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-hardware-team-ramp-up-future-devices-incoming-ceo-john-ternus/cZXuxbgReNK">Apple Reportedly Plans Hardware Team Shake Up To Ramp Up Future Devices As It Gears Up For Incoming CEO John Ternus</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Amer Sports climbed on Tuesday. (Representative image: Getty Images)

Relay Therapeutics Inc. (RLAY) shares declined more than 5% in Wednesday’s pre-market trade, extending the marginal decline on Tuesday, with the stock on track for its fifth consecutive trading session in the red.

Relay Therapeutics announced that it had commenced an offering of $175 million worth of shares of its common stock late Tuesday.

iShares Russell 2000 ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$RLAY Swing recap — target tagged, closing the loop. Plan posted Fri Oct 23: long shares, entry $18.11 (zone $18.00–$18.10), target $18.98, stop $17.63. I entered Mon Oct 26 — 7 shares at ~$18.15. Why it surfaced: a demand-zone scan caught the V-recovery off the $16.22 October low — a higher-low reclaim into a defended $17.90–$18.10 shelf. Data behind it: $911M cash with runway guided into 2029, so no financing overhang in the window; analyst panel 13-for-13 Buy-rated with a $28 median target; institutional ownership about 97%. What happened: price dipped to $17.68 Friday — just above the stop — pressed to $18.96 Tuesday (2 cents short), then ran through the $18.98 target Wednesday to a $19.705 high, closing at $19.69. Stop never tagged. Just the plan, posted before and after — no guarantees.

Feed

News

Sentiment

Earnings

Fundamentals

Info

RLAY Relay Therapeutics Inc

Fundamentals

Latest RLAY News